Drug Type Small molecule drug |
Synonyms ABSK043 |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemangiosarcoma | Phase 2 | Canada | 30 Jul 2025 | |
Intimal sarcoma | Phase 2 | Canada | 30 Jul 2025 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 2 | China | 25 Nov 2024 | |
Advanced Gastroesophageal Junction Adenocarcinoma | Phase 2 | China | 13 Nov 2024 | |
Advanced Urothelial Carcinoma | Phase 2 | China | 13 Nov 2024 | |
Gastrooesophageal junction cancer | Phase 2 | China | 13 Nov 2024 | |
metastatic non-small cell lung cancer | Phase 2 | China | 13 Nov 2024 | |
Unresectable Urothelial Carcinoma | Phase 2 | China | 13 Nov 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Australia | 24 Aug 2021 | |
KRAS G12C mutant Non-small Cell Lung Cancer | IND Approval | China | 19 Aug 2025 |
Phase 1 | 77 | asovpitswi(vkriilrnap) = tttfxpepva gkcqixmrpm (xhnsktjnhf ) View more | Positive | 06 Dec 2024 | |||
(the ICI-naïve pts) | zpbnrxnfxq(elqqtjgprl) = wdjhgakhdw sjqdmaituw (wipqtyuhvo ) | ||||||
NCT04964375 (ESMO2023) Manual | Phase 1 | 19 | flihuyelsn(vpyyhpqdon) = ejtiyfoubv sgtomatrvj (zabgmvdbol ) | Positive | 23 Oct 2023 |